Fluoxetine: Indication of inadequate use;Fluoxetina: Indícios de uso inadequado

Jornal Brasileiro de Psiquiatria

Volumn 58, Issue 2, 2009, Pages 97-100

  Carlini, Elisaldo A ^a   Noto, Ana Regina ^a   Nappo, Solange Aparecida ^a   Sanchez, Zila Van Der Meer ^a   Franco, Vera Lúcia Da Silva ^b   Silva, Luiz Carlos Franco ^b   Dos Santos, Vilmar Ezequiel ^b   Alves, Décio De Castro ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Laboratório Central de Saúde Pública do Estado da Bahia   (Brazil)

Author keywords

Antidepressant; Compounding pharmacy; Fluoxetine; Misuse; Weight loss

Indexed keywords

ACETYLSALICYLIC ACID; ALPRAZOLAM; AMOXAPINE; CARBAMAZEPINE; CYTOCHROME P450; DESIPRAMINE; DIAZEPAM; DICLOFENAC; DIPYRONE; FLUOXETINE; GINKGO BILOBA EXTRACT; PHENYTOIN; SIBUTRAMINE; ZOLPIDEM;

ARTICLE; BLOOD TOXICITY; BRAZIL; DEPRESSION; DRUG DOSE REGIMEN; DRUG MISUSE; GASTROINTESTINAL SYMPTOM; GENDER; GEOGRAPHIC DISTRIBUTION; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MENTAL DISEASE; NEPHROTOXICITY; NEUROTOXICITY; POLYPHARMACY; PRESCRIPTION; QT PROLONGATION; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; WEIGHT REDUCTION;

EID: 69549135168     PISSN: 00472085     EISSN: 19820208     Source Type: Journal    
DOI: 10.1590/S0047-20852009000200005     Document Type: Article

References (19)

1. Almeida-Filho N, Lessa I, Magalhães L, Araújo MJ, Aquino E, James AS, et al. Social inequality and depressive disorders in Bahia, Brazil: interactions of gender, ethnicity, and social class. Soc Sci Med. 2004;59:1339-1353 (Pubitemid 38891403)
2. Eap CB, Bondlli G, Zullino D, Savary-Consedai L, Golay KP, Kosel M, et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol. 2001;21:330-334 (Pubitemid 32452939)
3. Edwards JC. Drug choice in depression. Selective serotonin reuptake inhibitors or tricyclic antidepressants. CNS Drugs. 1995;4:141-159
4. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Herbert P, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomized controlled trials. BMJ. 2005;330: 396-399 (Pubitemid 40288826)
5. Hamelin B, Turgeon J, Vallée F, Bélanger PM, Paquer F, Lebel M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther. 1996;60:512-521 (Pubitemid 26414087)
6. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001;104:173-192 (Pubitemid 32762271)
7. Levine LR, Rosenblatt S, Bosomworth J. Use of a serotonin re-uptake inibitor, fluoxetine, in the treatment of obesity. Int J Obesity. 1987;11(3):185-190 (Pubitemid 18012911)
8. Messiha FS. Review: Fluoxetine adverse effects and drug-drug interactions. Clin Toxicol. 1993;31:603-630
9. Nappo SA, Oliveira EM, Morosini S. Inappropriate prescribing of compounded antiobesity formulas in Brasil. Pharmacoepid Drug Safety. 1998;7:207-212 (Pubitemid 28335360)
10. Nappo SA, Tabach R, Noto AR, Galduroz JCF, Carlini EA. Use of anorectic amphetamine - like drugs by Brazilian women. Eating Behav. 2002;3:153-165 (Pubitemid 34546557)
11. Noto AR, Carlini EA, Mastroianni P, Alves VC, Galduroz JCF, Czimar J, et al. Analysis of prescription and dispensation of psychotropic medications in two cities in the State of São Paulo, Brazil. Rev Bras Psiquiat. 2002;24:68-73.
12. Organização Mundial de Saúde (OMS). Segurança dos medicamentos: um guia para detectar e notificar reações adversas a medicamentos. Brasília: OPAS/OMS; 2004. 18 p.
13. O'Shea B. Antidepressants: user and attitudes among consultant psychiatrists. Br J Psychosocial Med. 1991;8:167-170
14. Preskorn SH. Debate resolved: there are differential effects of serotonin reuptake inhibitors on cytochrome P450 enzymes. J Psychopharmacol. 1998;13(B):S89-97.
15. Reactions Weekly. Brazilian diet pills may be harmful, warns FDA. Reactions Weekly. 2006;1085:3.
16. Schatzberg AF, Dessain E, O'Neil R, Katz DL, Cole JO. Recent studies on selective serotonergic antidepressants: trazodone, fluoxetine, fluvoxamine. J Clin Psychopharmacol. 1987; 7(6):445-495 (Pubitemid 18014275)
17. Stark P, Hardison CD. A review: multicenter controlled center of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry. 1987;46:53-58 (Pubitemid 15139191)
18. Tamminga WJ, Wemer J, Oosterhuis B, Zeweew RA, Leij LFMH, Jonkman JHG. The prevalence of CYP2D6 and CYP2C19 in a population of healthy Dutch volunteers. Eur J Clin Pharmacol. 2001;57:717-722 (Pubitemid 34031264)
19. Tiihonen J, Longvist J, Walbeck K, Klaukka T, Tansknen A, Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry. 2006;63:1358-1367 (Pubitemid 44878519)